Signatur Biosciences raises £5m seed led by The Discovery Lab to decentralise breast cancer prognostic testing

Signatur Biosciences develops decentralised molecular diagnostic tests that allow hospitals to run breast cancer prognostic testing locally, delivering faster results and reducing reliance on costly, centralised overseas laboratories.